Please login to the form below

Not currently logged in
Email:
Password:

pneumococcal disease

This page shows the latest pneumococcal disease news and features for those working in and with pharma, biotech and healthcare.

CHMP thumbs up for Novo's obesity drug Saxenda

CHMP thumbs up for Novo's obesity drug Saxenda

prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older. ... The vaccine is currently approved in Europe for the prevention of invasive pneumococcal disease in the same population.

Latest news

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    Meanwhile, Merck said it was pleased that Pneumovax 23 would continue to play an integral role in helping to prevent pneumococcal disease in adults who are at increased risk. ... Pneumococcal disease is still a significant burden and millions of adults

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    Pfizer closes on $1bn label expansion for Prevenar. EMA begins review of the pneumococcal vaccine. ... The vaccine is already approved in Europe for preventing invasive pneumococcal disease in adults, a less common but more serious infection

  • Pfizer acquires Baxter Men C and encephalitis vaccines for $635m Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

    Susan Silbermann, president of Pfizer Vaccines, said: “ For over a decade Pfizer has been the global leader in pneumococcal disease prevention. ... The company's deal with Pfizer did not include either its influenza vaccine development programme, nor

  • GSK and Pfizer extend vaccine access programme GSK and Pfizer extend vaccine access programme

    GSK and Pfizer extend vaccine access programme. Pharma companies lower price of pneumococcal vaccines for developing nations. ... GSK will provide Synflorix at a cost of $3.40 per dose up to 2024, with the company claiming it will help protect an

  • Pfizer wins new European approval for Prevenar 13 Pfizer wins new European approval for Prevenar 13

    Pfizer wins new European approval for Prevenar 13. Expands use of pneumococcal disease vaccine to cover people aged 18 to 49. ... Pfizer's Prevenar 13 yesterday became the first vaccine available in Europe to protect against pneumococcal disease for

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics